ArticleHuman cell2020
MiR-125b-5p suppresses the bladder cancer progression via targeting HK2 and suppressing PI3K/AKT pathway.
Article in Human cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Exploration of key drug target proteins highlighting their related regulatory molecules, functional pathways and drug candidates associated with delirium: evidence from meta-data analyses.BMC geriatrics · 2023Pooled it
- Exploring the role of metabolic disorders and gut microbiome in immune checkpoint regulation in cancer: PI3K/AKT/mTOR focus.Journal of physiology and biochemistry · 2026Review
- Aerobic glycolysis in bladder cancer: research advances and targeted therapy potential.Frontiers in oncology · 2026Review
- Review
- Nuclear Receptors in Bladder Cancer: Insights into miRNA-Mediated Regulation and Potential Therapeutic Implications.International journal of molecular sciences · 2025Review
- Bone mesenchymal stem cell‑derived exosome‑encapsulated microRNA‑125b‑5p inhibits ovarian cancer progression via DDX5 downregulation.Oncology letters · 2025Article
- Advances in S100 protein family for gynecological malignancies.Discover oncology · 2025Review
- Natural compounds as modulators of miRNAs: a new frontier in bladder cancer treatment.Medical oncology (Northwood, London, England) · 2025Review
- SRC enhanced cisplatin resistance in bladder cancer by reprogramming glycolysis and pentose phosphate pathway.Communications biology · 2025Article
- Identification of exosomal microRNAs and related hub genes associated with imatinib resistance in chronic myeloid leukemia.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Bladder cancer: non-coding RNAs and exosomal non-coding RNAs.Functional & integrative genomics · 2024Review
- The interaction of mast cells with membranes from lung cancer cells induces the release of extracellular vesicles with a unique miRNA signature.Scientific reports · 2023Article
- Targeted therapies in bladder cancer: signaling pathways, applications, and challenges.MedComm · 2023Review
- Article
- MiR-125b-5p Targets MTFP1 to Inhibit Cell Proliferation, Migration, and Invasion and Facilitate Cell Apoptosis in Endometrial Carcinoma.Molecular biotechnology · 2023Article
- Role of microRNAs in glycolysis in gynecological tumors (Review).International journal of oncology · 2023Review
- Acinous cell AR42J-derived exosome miR125b-5p promotes acute pancreatitis exacerbation by inhibiting M2 macrophage polarizationWorld journal of gastrointestinal surgery · 2023Article
- Integrated Microarray-Based Data Analysis of miRNA Expression Profiles: Identification of Novel Biomarkers of Cisplatin-Resistance in Testicular Germ Cell Tumours.International journal of molecular sciences · 2023Article
- Article
- Effect of Nanoparticles of DOX and miR-125b on DNA Damage Repair in Glioma U251 Cells and Underlying Mechanisms.Molecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer (BCa) is identified as the most common malignant solid cancer in the urogenital tract. Recently, dysregulation of miRNAs has received more attention because of its extensive role in the carcinogenesis of BCa. This research was designed to verify how miR-125b-5p be involved in BCa development. The expression of miR-125b-5p was detected in 52 pairs of BCa specimens and adjacent normal bladder specimens. The effects of miR-125b-5p on BCa viability, migration, and apoptosis in vitro were examined. We then examined directly target gene(s) of miR-125b-5p in BCa cells. Our data demonstrated that miR-125b-5p was decreased in BCa tissues and cell lines. Patients with low miR-125b-5p expression had obviously shorter 5-year survival time. Lower miR-125b-5p expression was significant correlated with distant metastasis, tumor size and lymph node metastasis. Ectopic expression of miR-125b-5p inhibited the BCa cell viability and migration and induced cell apoptosis. Furthermore, HK2 was confirmed regulated by miR-125b-5p. HK2 recovered miR-125b-5p-mediated suppression of BCa cell viability and migration. In addition, miR-125b-5p also exhibited suppressive effect on PI3K/AKT pathway. Overall, these data indicate that miR-125b-5p played a role in the suppressive effect on BCa by targeting HK2 through suppressing PI3K/AKT pathway and offer a potential therapeutic target for BCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.